{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T05:04:52Z","timestamp":1733547892205,"version":"3.30.1"},"reference-count":28,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2024.2024.0220","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T06:31:51Z","timestamp":1724308311000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Safety and Efficacy of Emicizumab Prophylaxis in Egyptian Pediatric Patients with Hemophilia A: Single Center Cross Sectional Study"],"prefix":"10.4274","author":[{"given":"Tamer","family":"Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manar","family":"Fathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Farag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Abdelhady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"Gameil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa Abu","family":"Hashem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","unstructured":"1. Berntorp E, Fischer K, Hart DP, Mancuso ME, Stephensen D, Shapiro AD, Blanchette V. Haemophilia. Nat Rev Dis Primers. 2021;7:45.","journal-title":"Nat Rev Dis Primers"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Majid Z, Tahir F, Qadar LT, Shaikh MY, Mahmood Shah SM. Hemophilia A with a rare presentation of hemarthrosis and arthropathy involving multiple joints in a young male child. Cureus. 2019;11:e4524.","DOI":"10.7759\/cureus.4524"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Lai JD, Lillicrap D. Factor VIII inhibitors: advances in basic and translational science. Int J Lab Hematol. 2017;39(Suppl 1):6-13.","DOI":"10.1111\/ijlh.12659"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Unim B, Veneziano MA, Boccia A, Ricciardi W, La Torre G. Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demand. ScientificWorldJournal. 2015;596164.","DOI":"10.1155\/2015\/596164"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.blre.2013.06.002","article-title":"Hemophilia A in the third millennium","volume":"27","author":"Franchini","year":"2013","unstructured":"5. Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev. 2013;27:179-184.","journal-title":"Blood Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/PROM.S44694","article-title":"A systematic review of patient-reported measures of burden of treatment in three chronic diseases","volume":"4","author":"Eton","year":"2013","unstructured":"6. Eton DT, Elraiyah TA, Yost KJ, Ridgeway JL, Johnson A, Egginton JS, Mullan RJ, Murad MH, Erwin PJ, Montori VM. A systematic review of patient-reported measures of burden of treatment in three chronic diseases. Patient Relat Outcome Meas. 2013;4:7-20.","journal-title":"Patient Relat Outcome Meas"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bjh.13365","article-title":"The current status of prophylactic replacement therapy in children and adults with haemophilia","volume":"169","author":"Ljung","year":"2015","unstructured":"7. Ljung R, Gretenkort Andersson N. The current status of prophylactic replacement therapy in children and adults with haemophilia. Br J Haematol. 2015;169:777-786.","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, Yoshihashi K, Harada A, Funaki M, Haraya K, Tachibana T, Suzuki S, Esaki K, Nabuchi Y, Hattori K. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8:e57479.","DOI":"10.1371\/journal.pone.0057479"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1080\/14740338.2019.1551356","article-title":"Evaluating the safety of emicizumab in patients with hemophilia A","volume":"17","author":"Langer","year":"2018","unstructured":"9. Langer AL, Etra A, Aledort L. Evaluating the safety of emicizumab in patients with hemophilia A. Expert Opin Drug Saf. 2018;17:1233-1237.","journal-title":"Expert Opin Drug Saf"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Jim\u00e9nez-Yuste V, Peyvandi F, Klamroth R, Castaman G, Shanmukhaiah C, Rangarajan S, Garc\u00eda Chavez J, Martinez R, Kenet G, Alzahrani H, Robson S, Schmitt C, Kiialainen A, Meier O, Ozelo M. Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY). Res Pract Thromb Haemost. 2022;6:e12837.","DOI":"10.1002\/rth2.12837"},{"key":"ref10","unstructured":"11. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Bethesda, NCI, 2009. Available online at https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: Communication from the SSC of the ISTH","volume":"12","author":"VS","year":"2014","unstructured":"12. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: Communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:1935-1939.","journal-title":"J Thromb Haemost"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/jth.14491","article-title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program","volume":"17","author":"Levy","year":"2019","unstructured":"13. Levy GG, Asikanius E, Kuebler P, Benchikh El Fegoun S, Esbjerg S, Seremetis S. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program. J Thromb Haemost. 2019;17:1470-1477.","journal-title":"J Thromb Haemost"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","unstructured":"14. Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, Mahlangu J, Young G, Kruse-Jarres R, Mancuso ME, Niggli M, Howard M, Bienz NS, Shima M, Jim\u00e9nez-Yuste V, Schmitt C, Asikanius E, Levy GG, Pipe SW, Oldenburg J. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021;137:2231-2242.","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/hae.14005","article-title":"Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures","volume":"26","author":"McCary","year":"2020","unstructured":"15. McCary I, Guelcher C, Kuhn J, Butler R, Massey G, Guerrera MF, Ballester L, Raffini L. Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures. Haemophilia. 2020;26:631-636.","journal-title":"Haemophilia"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4103\/GJTM.GJTM_35_19","article-title":"\"Prevalence of inhibitors in hemophilia patients and its clinical implications\": a study of 276 patients in Western India","volume":"4","author":"Shah","year":"2019","unstructured":"16. Shah SD, Patel TR, Bhatnagar NM, Gajjar MD, Shah MC, Tripathi S. \"Prevalence of inhibitors in hemophilia patients and its clinical implications\": a study of 276 patients in Western India. Glob J Transfus Med. 2019;4:168-174.","journal-title":"Glob J Transfus Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"SC","year":"2013","unstructured":"17. Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, M\u00e4kipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368:231-239.","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","unstructured":"18. Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Hanagavadi S, Varadarajan R, Karimi M, Manglani MV, Ross C, Young G, Seth T, Apte S, Nayak DM, Santagostino E, Mancuso ME, Sandoval Gonzalez AC, Mahlangu JN, Bonanad Boix S, Cerqueira M, Ewing NP, Male C, Owaidah T, Soto Arellano V, Kobrinsky NL, Majumdar S, Perez Garrido R, Sachdeva A, Simpson M, Thomas M, Zanon E, Antmen B, Kavakli K, Manco-Johnson MJ, Martinez M, Marzouka E, Mazzucconi MG, Neme D, Palomo Bravo A, Paredes Aguilera R, Prezotti A, Schmitt K, Wicklund BM, Zulfikar B, Rosendaal FR. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374:2054-2064.","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.5045\/br.2019.54.3.204","article-title":"The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A","volume":"54","author":"JY","year":"2019","unstructured":"19. Kim JY, You CW. The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A. Blood Res. 2019;54:204-209.","journal-title":"Blood Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/JBM.S50644","article-title":"Optimal management of hemophilic arthropathy and hematomas","volume":"5","author":"Lobet","year":"2014","unstructured":"20. Lobet S, Hermans C, Lambert C. Optimal management of hemophilic arthropathy and hematomas. J Blood Med. 2014;5:207-218.","journal-title":"J Blood Med"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Reding MT, Pabinger I, Lalezari S, Santagostino E, Mancuso ME. Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027. Haemophilia. 2020;26:e201-e204.","DOI":"10.1111\/hae.13982"},{"key":"ref21","unstructured":"22. Abdelwahab M, Elghamrawy M, Seifeldeen H, Fathi N. Outcome of emicizumab in management of Egyptian children and adolescents with hemophilia A with inhibitors: a 2 year single center prospective study. Virtual presentation, International Society on Thrombosis and Haemostasis, 2022. Abstract available at https:\/\/www.eventscribe.net\/2022\/program\/fsPopup.asp?efp=TUZOTFdCREsxNjMzMw&PresentationID =1078664&rnd=0.9619532&mode=presinfo"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","unstructured":"23. Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809-818.","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","unstructured":"24. Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jim\u00e9nez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379:811-822.","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, Key NS, Portron A, Schmitt C, Podolak-Dawidziak M, Selak Bienz N, Hermans C, Campinha-Bacote A, Kiialainen A, Peerlinck K, Levy GG, Jim\u00e9nez-Yuste V. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6:e295-e305.","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","unstructured":"26. Shima M, Nogami K, Nagami S, Yoshida S, Yoneyama K, Ishiguro A, Suzuki T, Taki M. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia. 2019;25:979-987.","journal-title":"Haemophilia"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/08880018.2021.2004269","article-title":"Breakthrough bleeding episodes in pediatric severe hemophilia A patient with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review","volume":"39","author":"Hassan","year":"2022","unstructured":"27. Hassan E, Motwani J. Breakthrough bleeding episodes in pediatric severe hemophilia A patient with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review. Pediatr Hematol Oncol. 2022;39:418-426.","journal-title":"Pediatr Hematol Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","unstructured":"28. Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jim\u00e9nez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134:2127-2138.","journal-title":"Blood"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T06:50:44Z","timestamp":1733467844000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-20587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":28,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2024.2024.0220","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"type":"print","value":"1300-7777"},{"type":"electronic","value":"1308-5263"}],"subject":[],"published":{"date-parts":[[2024,8,22]]}}}